Compare Altria Group Inc (MO) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs Organon & Co. Common Stock — how do they compare? Altria Group Inc trades at $73.89 (market cap $122.11B), while Organon & Co. Common Stock trades at $13.76 (market cap $3.61B). The key difference: Altria Group Inc is far larger — about 33.8× Organon & Co. Common Stock's market cap, and Altria Group Inc pays the higher dividend (6.07%). Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 155 Days and Organon & Co. Common Stock for 0 Days on average.
| MO | OGN | |
|---|---|---|
Market Cap | $122.11B | $3.61B |
Volume | 5,621,141 | 1,808,049 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $13.81 |
52-Week Low | $54.72 | $5.70 |
Typical Hold Time | 155 Days | 0 Days |
Enterprise Value | $144.32B | $11.03B |
Dividend Yield | 6.07% | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $73.89, up 3.26% today, with a bullish technical signal from moving averages but bearish oscillators. The stock shows strong profitability with a 39% net income margin and a P/E of 15.4, though revenue has been flat near $20.1B in 2025. Recent earnings have been mixed, with a Q1 2026 beat but Q2 and Q4 2025 misses. The company maintains a high dividend yield, supported by $9.29B in operating cash flow, but faces scrutiny over negative shareholder equity and regulatory pressures.
Outlook: MO offers a high dividend yield and stable cash flows, appealing for income investors, but risks include declining cigarette volumes, regulatory hurdles for smoke-free products, and a leveraged balance sheet. Analyst consensus is bullish with a $69.71 price target, yet negative equity and margin pressures warrant caution for growth-focused investors.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
